Beam Therapeutics Stock Beta
| BEAM Stock | USD 26.65 1.60 6.39% |
Beam Therapeutics fundamentals help investors to digest information that contributes to Beam Therapeutics' financial success or failures. It also enables traders to predict the movement of Beam Stock. The fundamental analysis module provides a way to measure Beam Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Beam Therapeutics stock.
Beam | Beta |
Beam Therapeutics Company Beta Analysis
Beam Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Beam Therapeutics Beta | 1.86 |
Most of Beam Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Beam Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Beam Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Beam Therapeutics is extremely important. It helps to project a fair market value of Beam Stock properly, considering its historical fundamentals such as Beta. Since Beam Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Beam Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Beam Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Beam Therapeutics has a Beta of 1.862. This is 116.51% higher than that of the Biotechnology sector and 33.96% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Beam Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Beam Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Beam Therapeutics could also be used in its relative valuation, which is a method of valuing Beam Therapeutics by comparing valuation metrics of similar companies.Beam Therapeutics is currently under evaluation in beta category among its peers.
Beam Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Beam Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Beam Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Beam Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Beam Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Beam Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Beam Therapeutics' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.8 M | Redmile Group, Llc | 2024-09-30 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | Bellevue Group Ag | 2024-09-30 | 1.5 M | Citadel Advisors Llc | 2024-09-30 | 1.5 M | First Trust Advisors L.p. | 2024-06-30 | 1.5 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | Kynam Capital Management, Lp | 2024-09-30 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | Farallon Capital Management, L.l.c. | 2024-09-30 | 8.2 M | Vanguard Group Inc | 2024-09-30 | 7.8 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Beam Therapeutics will likely underperform.
Beam Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0928 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (7.46) % | ||||
| Current Valuation | 1.31 B | ||||
| Shares Outstanding | 82.81 M | ||||
| Shares Owned By Insiders | 1.41 % | ||||
| Shares Owned By Institutions | 93.10 % | ||||
| Number Of Shares Shorted | 12.31 M | ||||
| Price To Earning | 37.48 X | ||||
| Price To Book | 2.62 X | ||||
| Price To Sales | 5.93 X | ||||
| Revenue | 377.71 M | ||||
| Gross Profit | (250.67 M) | ||||
| EBITDA | (156.47 M) | ||||
| Net Income | (132.53 M) | ||||
| Cash And Equivalents | 1.09 B | ||||
| Cash Per Share | 15.90 X | ||||
| Total Debt | 173.17 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 4.64 X | ||||
| Book Value Per Share | 9.97 X | ||||
| Cash Flow From Operations | (149.19 M) | ||||
| Short Ratio | 13.00 X | ||||
| Earnings Per Share | (1.58) X | ||||
| Price To Earnings To Growth | (2.30) X | ||||
| Target Price | 49.2 | ||||
| Number Of Employees | 472 | ||||
| Beta | 1.86 | ||||
| Market Capitalization | 2.07 B | ||||
| Total Asset | 1.46 B | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 1.01 B | ||||
| Current Asset | 2.89 B | ||||
| Current Liabilities | 706.6 M | ||||
| Net Asset | 1.46 B |
About Beam Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Beam Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Beam Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Beam Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Beam Therapeutics Piotroski F Score and Beam Therapeutics Altman Z Score analysis. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.